Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC ; volume:41 ; number:8 ; day:25 ; month:6 ; year:2024 ; pages:3217-3231 ; date:8.2024
Advances in therapy ; 41, Heft 8 (25.6.2024), 3217-3231, 8.2024
- Creator
-
Arnaoutakis, Konstantinos
Wan, Yin
Elliott, Jennifer
Young, Matt
Yin, Yu
Leventakos, Konstantinos
Lin, Huamao M.
Dimou, Anastasios
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-024-02899-6
- URN
-
urn:nbn:de:101:1-2410072110052.342860858875
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
07.08.2025, 11:29 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Arnaoutakis, Konstantinos
- Wan, Yin
- Elliott, Jennifer
- Young, Matt
- Yin, Yu
- Leventakos, Konstantinos
- Lin, Huamao M.
- Dimou, Anastasios
- SpringerLink (Online service)
Other Objects (12)
Alecensa bei ALK-positivem NSCLC
Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
Inhibiting ALK-TOPK signaling pathway promotes cell apoptosis of ALK-positive NSCLC
Therapie des ALK+ NSCLC - Brigantinib in der Erstlinie [1, 3] : nicht-kleinzelliges Lungenkarzinom (NSCLC)
ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC
Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC
Brigatinib : neue Option in der Zweitlinie für Crizotinibvorbehandelte, ALK+ NSCLC Patienten
Successful salvage surgery followed by second ALK–TKI after alectinib failure in a patient with ALK-positive NSCLC
Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis
Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs
ALK-positives NSCLC: signifikant verbessertes progressionsfreies Überleben unter Brigatinib : Erfahrungsberichte aus dem Alltag
Alecensa bei ALK-positivem NSCLC
Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
Inhibiting ALK-TOPK signaling pathway promotes cell apoptosis of ALK-positive NSCLC
Therapie des ALK+ NSCLC - Brigantinib in der Erstlinie [1, 3] : nicht-kleinzelliges Lungenkarzinom (NSCLC)
ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC
Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC
Brigatinib : neue Option in der Zweitlinie für Crizotinibvorbehandelte, ALK+ NSCLC Patienten
Successful salvage surgery followed by second ALK–TKI after alectinib failure in a patient with ALK-positive NSCLC
Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis
Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs
ALK-positives NSCLC: signifikant verbessertes progressionsfreies Überleben unter Brigatinib : Erfahrungsberichte aus dem Alltag
Alecensa bei ALK-positivem NSCLC
Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
Inhibiting ALK-TOPK signaling pathway promotes cell apoptosis of ALK-positive NSCLC
Therapie des ALK+ NSCLC - Brigantinib in der Erstlinie [1, 3] : nicht-kleinzelliges Lungenkarzinom (NSCLC)
ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC
Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC
Brigatinib : neue Option in der Zweitlinie für Crizotinibvorbehandelte, ALK+ NSCLC Patienten
Successful salvage surgery followed by second ALK–TKI after alectinib failure in a patient with ALK-positive NSCLC
Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis
Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs